KEYNOTE-A18 / ENGOT-cx11 / GOG-3047
Adding immunotherapy to curative chemoradiation for locally advanced cervical cancer improved both control and survival, the first such advance in two decades.
24-month PFS 68% vs 57% (HR 0.70; Lancet 2024). 36-month OS 82.6% vs 74.8% (HR 0.67; Lancet 2024 OS paper). FDA approval January 2024 for FIGO 2014 stage III-IVA disease; the first change to the cisplatin-radiation standard set in 1999.
- 68 vs 57 out of 100 alive without the cancer growing at 24 months with Pembrolizumab + CRT compared with Placebo + CRT; 11 more per 100.
- Roughly one extra person helped for every 9 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7, likely range 0.55 to 0.89).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 82.6 vs 74.8 out of 100 alive at 36 months with Pembrolizumab + CRT compared with Placebo + CRT; 7.8 more per 100.
- Roughly one extra person helped for every 13 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 33 percent lower chance of the event at any given time (hazard ratio 0.67, likely range 0.5 to 0.9).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Newly diagnosed high-risk locally advanced cervical cancer (FIGO 2014 IB2-IIB node-positive or III-IVA): pembrolizumab + cisplatin chemoradiation + brachytherapy, then pembrolizumab, vs chemoradiation. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,060 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival at 24 monthsprimary | Pembrolizumab + CRT | 529 | 68% | 0.7 (0.55–0.89) | — | link |
| Placebo + CRT | 531 | 57% | ||||
| Overall survival at 36 monthsprimary | Pembrolizumab + CRT | — | 82.6% | 0.67 (0.5–0.9) | — | link |
| Placebo + CRT | — | 74.8% |
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-826
Shares Cisplatin, Cervical cancer, PD-1, Pembrolizumab.
- TrialNRG-GY018 / KEYNOTE-868
Shares Society of Gynecologic Oncology, GOG Foundation, PD-1, Pembrolizumab.
- TrialINTERLACE
Shares Cisplatin, Brachytherapy, IMRT / IGRT (modern external beam), Cervical cancer.
- Key paperKEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer
Shares Brachytherapy, IMRT / IGRT (modern external beam), Cervical cancer, PD-1.
- PairingRadiotherapy + immunotherapy
Shares PD-1 blockade + chemoradiation (locally advanced cervical cancer), Cervical cancer, Pembrolizumab, Immune checkpoint inhibitors.
- TrialRUBY / ENGOT-EN6 / GOG-3031
Shares Society of Gynecologic Oncology, GOG Foundation, PD-1.
- TrialOUTBACK / ANZGOG 0902 / GOG-0274
Shares GOG Foundation, IMRT / IGRT (modern external beam), Cervical cancer.
- CancerVulvar cancer
Shares Cisplatin, IMRT / IGRT (modern external beam), PD-1, Pembrolizumab.